Volume 7, Issue 1, January 2018, Page: 26-29
Evaluation of Antistreptolysin O (ASO) Titer in Rheumatoid Heart Disease Debre Berhan Referral Hospital, Ethiopia
Tsegahun Asfaw, Department of Medical Laboratory Science, Debre Berhan University, Debrebirhan, Ethiopia
Demissew Shenkute, Department of Medical Laboratory Science, Debre Berhan University, Debrebirhan, Ethiopia
Mihret Tilahun, Department of Medical Laboratory Science, Debre Berhan University, Debrebirhan, Ethiopia
Nigus Zegeye, Department of Medical Laboratory Science, Debre Berhan University, Debrebirhan, Ethiopia
Received: Feb. 14, 2018;       Accepted: Mar. 7, 2018;       Published: Mar. 29, 2018
DOI: 10.11648/j.cmr.20180701.14      View  1043      Downloads  32
Abstract
Introduction: Rheumatic heart disease (RHD) remain significant causes of cardiovascular disease and mortality in children particularly in the developing countries. This study aims to evaluate ASO titer in rheumatic heart disease patients who are on secondary prophylaxis. Methods: A cross sectional study method was employed to collect blood sample from RHD patients (children) who are on secondary prophylaxis at pediatric clinic of Debre Brehan referral hospital. The blood sample was collected, transported and processed based on standard operating procedures (SOPs) for ASO titer determination. And finally, the data was analyzed using SPSS version 21and P-value less than or equal to 0.05 was taken as statistically significant. Result: A total of 123 children on secondary prophylaxis for RHD; in the age range of 5-15 years are included. Of these, 65 (52.8) were male and 58 (47.2%) were female; 69 (56.1%) were from rural and 54 (43.9%) were from urban area. The highest frequency of participant 52 (42.3%) were in the age group of 9-12 years. Among participants 74 (60.2%) had history of pharyngitis. The result of ASO titer shows 78 (63.4%) were positive in antistreptolysin O slide agglutination test; 30 (24.4%) patients have 400IU/ml ASO titer, 19 (15.4%) patients have 600 IU/ml ASO titer, 17 (13.8%) patients have ASO titer 800 IU/ml and 12 (9.8%) patients have ASO titer >1000 IU/ml. Conclusion: This study suggest that in most children admitted with RHD have recent streptococcal infection as evident by raised ASO titer.
Keywords
Children, Rheumatic Heart Disease, ASO Titers, Risk Factors, Ethiopia
To cite this article
Tsegahun Asfaw, Demissew Shenkute, Mihret Tilahun, Nigus Zegeye, Evaluation of Antistreptolysin O (ASO) Titer in Rheumatoid Heart Disease Debre Berhan Referral Hospital, Ethiopia, Clinical Medicine Research. Vol. 7, No. 1, 2018, pp. 26-29. doi: 10.11648/j.cmr.20180701.14
Copyright
Copyright © 2018 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Wood H, Feinstein AR, Taranta A, Epstein JA, Simpson R. (1964). Rheumatic fever in children and adolescents: a long-term epidemiologic study of subsequent prophylaxis, streptococcal infections, and clinical sequelae: III. Comparative effectiveness of three prophylaxis regiments in preventing streptococcal infection and rheumatic recurrences. Annals of Internal Medicine, 60:31-46.
[2]
Bland E and Jones T. (1951). Rheumatic fever and rheumatic heart disease. A twenty-year report on 1,000 patients followed since childhood. Circulation, 4:836-43.
[3]
Tompkins DG, Boxerbaum B and Liebman J. (1972) Long-term prognosis of rheumatic fever patients receiving regular intramuscular benzathine penicillin. Circulation, 543-51.
[4]
Lozano MN, Foreman K, Lim S, Shibuya K, Aboyans V, et al. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, 380 (9859):2095-128.
[5]
Roberts KCS, Steer A, Reményi B, Carapetis J. (2013). Screening for rheumatic heart disease: current approaches and controversies. Nature Reviews Cardiology, 10 (1):49-58.
[6]
Carapetis JR, Steer AC, Mulholland EK, Weber M. (2005). The global burden of group A streptococcal diseases. The Lancet Infectious Diseases, 5:685-94.
[7]
Oli K, Porteous J. (1999). Prevalence of rheumatic heart disease among school children in Addis Ababa. East African Medical Journal, 76:601-5.
[8]
Oli K, Tekle-Haimanot R, Forsgren L, Ekstedt J. (1992) Rheumatic heart disease prevalence among schoolchildren of an Ethiopian rural town. Cardiology, 80 (2):152-5.
[9]
Mandor BI, Asuquo AE, Abia-Bassey L, Benjamin TP, Akpan IA, Meremiku MM, Etuk IS, et al. (2013). Antistreptolysin O (ASO) titers and beta-haemolytic streptococcus (BHS) in Children in Calabar, Nigeria. IOSR Journal of Nursing and Health Science, 1 (5): 42-46.
[10]
Martin DR., Voss LM, Walker SJ and Lennon D. (1994). Acute rheumatic fever in Auckland, New Zealand: spectrum of associated group A streptococci different from expected. The Pediatrics Infectious Diseases Journal, 13:264-269.
[11]
Shet A and Kaplan EL. (2002) Clinical use and interpretation of group A streptococcal antibody tests: a practical approach for the pediatrician or primary care physician. The Pediatrics Infectious Diseases Journal, 21:420-426.
[12]
Klein GC, Baker CN, and Jones WL. (1971) “Upper limits of normal” antistreptolysin O and antideoxyribonuclease B titers. Applied Microbiology, 21: 999-1001.
[13]
Abdul Sattar, Shaukat Ali, Abdul Wadood, Nida Ali and Shamila Afshan. (2015) Evaluation of anti-streptolysin O titers in rheumatic heart disease patients. Journal Sheikh Zayed Medical College, 6 (2):808-810.
[14]
Gerber MA, Baltimore RS, Eaton CB, et al. (2009). Prevention of rheumatic fever and diagnosis and treatment of acute Streptococcal pharyngitis: a scientific statement from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young, the Interdisciplinary Council on Functional Genomics and Translational Biology, and the Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. Circulation, 119:1541-51.
[15]
Alyaa Amal Kotby, Nevin Mamdouh Habeeb and Sahar Ezz El Elarab. (2012) Antistreptolysin O titer in health and disease: levels and significance. Pediatric Reports; 4:e8.
[16]
Dajani AS. (2005). Rheumatic fever. In: Braunwald E, ed. Heart disease: A Text book of Cardiovascular Medicine.7th ed. Philadelphia, PA: WB Saunders; 2093-2100.
Browse journals by subject